RGEN - Here's Why Repligen Stock Tumbled 17.4% in September
Shares of Repligen (NASDAQ: RGEN) fell more than 17% last month, according to data provided by S&P Global Market Intelligence. In fact, September was the stock's worst month of 2019, although there wasn't any company-specific news to justify the drop. This simply appears to be a case of investors taking some gains off the table for a company trading at a healthy premium.
For instance, even when accounting for September's tumble, shares of Repligen have gained 45% since the beginning of the year. The $3.9 billion company trades at 71 times future estimated earnings, 17 times sales, and four times book value. That's been the case for much of the last five years or so, but the bioprocess leader has always managed to grow into its premium valuation. Can that continue?
Image source: Getty Images.